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ABSTRACT
Objectives Estimate and compare the risk of mortality in 
patients whose antidiabetic therapy is modified to include 
pioglitazone compared with an alternative antidiabetic 
medication at the same stage of disease progression.
Design Retrospective cohort study.
Setting Pooled analysis of clinical data collected from 
primary and/or secondary care settings in four European 
countries: Finland, The Netherlands, Sweden and the UK .
Participants 56 337 patients with type 2 diabetes 
mellitus first prescribed pioglitazone between 2000 and 
2011, and 56 337 patients never prescribed pioglitazone 
matched by treatment stage, history of diabetes, diabetes 
complications and cardiovascular disease, and year of 
cohort entry using exact and propensity score matching. 
Patients were followed-up for a mean of 2.90 (SD 2.21) 
and 2.83 (SD 2.37) years in the pioglitazone-exposed and 
non-pioglitazone-exposed groups, respectively.
Outcomes All-cause mortality ascertained from clinical or 
registry data. Mortality was a planned secondary outcome 
in a study primarily studying the association of pioglitazone 
use with bladder cancer risk.
Results The crude overall mortality rate per 10 000 
patient years was 206 (95% CI 199 to 213) in the 
pioglitazone-exposed group and 448 (95% CI 438 to 458) 
in the non-pioglitazone-exposed group. The crude HR 
comparing pioglitazone to alternative antidiabetic exposure 
was 0.46 (95% CI 0.45 to 0.48). This reduced in magnitude 
to 0.67 (95% CI 0.64 to 0.70) following further adjustment 
for matching variables, propensity scores, age, gender and 
time-dependent variables representing use of alternative 
antidiabetic drugs.
Conclusions In this large observational cohort study of 
patients with type 2 diabetes, pioglitazone exposure was 
associated with a statistically significant decrease in the 
risk of all-cause mortality across four European countries. 
Results should be interpreted with caution due to the 
potential for residual confounding.
Protocol registration European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance.
INTRODUCTION
Newly diagnosed adult patients with diabetes 
have 5–10 years shorter life expectancy than 
the general population 1 2 with cardiovascular 
disease being the leading cause of death in 
this patient group. Randomized clinical 
trials (RCTs) demonstrate that antidiabetic 
medications including pioglitazone improve 
insulin sensitivity in insulin-resistant patients 
resulting in lower plasma glucose and insulin 
concentrations and lower HbA1c values.3–5 
Use of pioglitazone in combination with 
sulfonylurea, metformin or insulin has an 
additive effect in patients with type 2 diabetes 
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Significance of this study
What is already known about this subject?
 ► Evidence from the large Prospective Pioglitazone 
Clinical Trial In Macrovascular Events  (PROactive) 
and Insulin Resistance Intervention after Stroke (IRIS) 
trials indicates that pioglitazone did not increase or 
reduce the risk of death from any cause in patients 
with type 2 diabetes at high-risk of cardiovascular 
disease (PROactive) or prediabetic patients with 
a history of ischemic stroke or transient ischemic 
attack (IRIS).
 ► Observational studies and meta-analyses of smaller 
randomized trials studying the risk of cardiovascular 
events have demonstrated a statistically significant 
reduction in the risk of all-cause mortality with 
pioglitazone use.
What are the new findings?
 ► This pan-European, observational, retrospective 
large cohort study indicates that prescribing 
pioglitazone compared with an alternative treatment 
decision at the same stage of disease progression 
was associated with a statistically significant 33% 
reduction in all-cause mortality.
How might these results change the focus of 
research or clinical practice?
 ► This further supports the safe use of pioglitazone. 
Additional research is recommended to evaluate 
the association of pioglitazone use with all-cause 
mortality.
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mellitus (T2DM).6–9 This reduction in HbA1c has been 
hypothesized to protect patients with T2DM from macro-
vascular complications and reduced life expectancy.10–13 
Meta-analyses of randomized trials studying the risk of 
cardiovascular events have demonstrated a statistically 
significant reduction in the risk of all-cause mortality with 
pioglitazone use.14 15 The more recent meta-analysis by 
Mannucci et al aimed to assess the association of piogli-
tazone treatment with risk of non-fatal coronary events, 
cardiovascular and all-cause mortality.15 The meta-analysis 
demonstrated a statistically significant association of piogl-
itazone with reduced all-cause mortality OR 0.30 (95% 
CI 0.14 to 0.63) in trials restricted to relatively low-risk 
patients with T2DM. Comparators in these trials included 
placebo, sulphonylureas (SU), metformin, rosiglitazone 
and glitazars. The large PROspective pioglitAzone Clin-
ical Trial In macroVascular Events (PROactive) trial,16 
conducted in high-risk patients with pre-existing macro-
vascular disease and T2DM, found that pioglitazone 
directionally reduced the risk of the composite primary 
endpoint—death from any cause, non-fatal myocar-
dial infarction (MI), stroke, acute coronary syndrome, 
leg amputation, coronary revascularization, or revas-
cularization of the leg (HR 0.90, 95% CI 0.80 to 1.02). 
However, pioglitazone use significantly reduced the main 
secondary endpoint of all-cause mortality, MI and stroke 
(HR 0.84, 95% CI 0.72 to 0.98). Fewer deaths contributed 
to the primary and secondary endpoint in the pioglita-
zone arm than the placebo arm. An observational study 
using US claims data found a significantly lower risk of 
all-cause mortality in patients with T2DM prescribed 
pioglitazone compared with insulin (HR 0.33, 95% CI 
0.31 to 0.36).17 More recently, a cohort study using data 
from a UK primary care database showed a decreased 
risk of all-cause mortality (HR 0.82, 95% CI 0.77 to 0.88), 
heart failure (HR 0.86, 95% CI 0.78 to 0.95) and cardio-
vascular (CV) disease (HR 0.94, 95% CI 0.88 to 1.00) 
with use of glitazones in T2DM compared with non-use 
of these agents.18 Pioglitazone was prescribed to 90% of 
glitazone users in the study as rosiglitazone was found to 
increase cardiovascular risk and withdrawn from the UK 
market in 2010.19
The primary objective of this pan-European multida-
tabase cohort study was to investigate the risk of bladder 
cancer associated with pioglitazone use compared with 
other diabetic drugs at the same stage of treatment in 
patients with T2DM. Results were recently published.20 
Here we present findings from the secondary outcomes: 
all-cause and bladder cancer-specific mortality.
METHODS
Study design and setting
This pan-European multidatabase retrospective cohort 
study used six non-overlapping datasets from four Euro-
pean countries: Finland (FIN), the Netherlands (NL), 
Sweden (SWE) and the United Kingdom (UK).
Data from the PHARMO Database Network and Clin-
ical Practice Research Datalink (CPRD) were used in the 
NL and UK, respectively.
Data sources
Drug exposure data were based on prescription data in 
the NL general practitioner (GP), UK GP, and UK GP 
hospital (GP-HOSP) datasets, and on dispensing data in 
the FIN, SWE and NL HOSP pharmacy (PHARM) data-
sets. All-cause and bladder cancer-specific (International 
Statistical Classification of Diseases and Related Health 
Problems 10th Revision (ICD-10) code C67) mortality 
were measured in linked national death records in 
FIN, SWE, NL-PHARM-HOSP and UK GP-HOSP data-
sets. All-cause mortality was identified using GP medical 
records in the NL GP and UK GP datasets. Further data 
to identify the study cohort and adjust for covariates 
was obtained from cancer registries, hospital discharge 
records, migration records, and national diabetes regis-
ters where available. The study period start and end dates 
respectively ranged by dataset from 1 Jan 2000 to 1 July 
2006 and from 31 December 2010 to 30 June 2011.
Participants
The study population included patients over the age 
of 40 with T2DM whose diabetic treatment regimen 
was altered to include pioglitazone or any other antidi-
abetic medication during the study period. Potential 
cohort entry dates (CEDs) were set as the date of the 
first-ever pioglitazone prescription for pioglitazone-ex-
posed patients and the date of switching to or add-on 
(initiation) of any other antidiabetic medication for the 
non-pioglitazone-exposed group. CEDs were excluded if 
there were under 12 months’ membership in the medi-
cation database, any indication of bladder cancer prior 
to the CED, or if patients were concurrently exposed to 
another thiazolidinedione.
Matching and covariates
Guidelines for prescription of antidiabetic drugs recom-
mend a stepwise approach that takes into account the 
efficacy of each drug substance in controlling blood sugars 
and the different safety profiles. Pioglitazone is therefore 
‘channelled’ to patients at a specific stage of diabetes and 
with other characteristics that affect their prognosis. The 
following approach was therefore taken in an attempt 
to eliminate channelling bias.21 Propensity scores (PSs) 
were estimated for each CED using a weighted logistic 
regression model with weights reciprocal to the number 
of CEDs per individual. The PS model included base-
line binary and categorical variables that were likely to 
have a direct impact on treatment choice and could be 
measured in all datasets. These included: antidiabetic 
treatment immediately prior to CED, whether the treat-
ment change at CED was an add-on or switch in therapy, 
use of thiazolidinediones prior to CED, duration of 
treated diabetes, number of different antidiabetic medi-
cations used prior to CED, history of MI, stroke, heart 
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failure, and the following diabetic complications, retinop-
athy or maculopathy, severe lower limb complications, 
renal complications, ketoacidosis, and hyperosmolar or 
ketoacidotic coma—duration of prescription database 
membership and calendar year of CED.
Pioglitazone CEDs were 1:1 fixed ratio matched and 
1:10 variable ratio matched to non-pioglitazone CEDs 
using the PS distance and the following exact matching 
variables: antidiabetic treatment immediately prior 
to CED, whether the treatment change at CED was an 
add-on or switch in therapy, and use of thiazolidinedi-
ones prior to CED. Non-pioglitazone exposed patients 
were removed from further matching when one of their 
CEDs was matched to a pioglitazone-exposed patient. 
The number of matched non-pioglitazone-exposed 
patients varied between patients and countries in the 
1:10 matched cohort resulting in an imbalance in charac-
teristics. The main analysis was therefore based on the 1:1 
fixed ratio matched cohort. Each patient was followed-up 
from CED until date of death or censorship due to end of 
membership of the database, end of database coverage, 
start of other thiazolidinediones or 30 June 2011. Time-
varying (TV) covariates were generated to improve the 
estimation of adjusted HR. New binary TV covariates 
for use of each alternative antidiabetic treatment class 
and comorbidity history were generated for inclusion or 
testing in the regression model. Use of antidiabetic treat-
ment group other than pioglitazone and comorbidity 
history was categorized as ever versus never used and ever 
versus never occurred up to any given time period. Age 
categories were fixed at baseline.
Statistical analysis
A pooled analysis was performed using all six cohorts. 
Descriptive data and standardized differences comparing 
the pioglitazone-exposed and non-pioglitazone-exposed 
groups were presented in the primary manuscript.20 
Crude all-cause and bladder cancer mortality rates were 
estimated with 95% CIs using Poisson regression. HR 
were generated using a Cox proportional hazards (PH) 
model including the ever versus never exposure variable 
and a categorical dataset variable. Adjusted models also 
included as covariates age, gender, antidiabetic medi-
cations, exact matching variables, PS quintiles, and all 
variables that were included in the PS. Further covariates 
were included as confounders if their inclusion resulted 
in a minimum of 10% change in the HR of primary 
exposure (ever vs never exposed to pioglitazone) when 
introduced into the crude model. The PH assumption 
was examined by inspection of the Kaplan-Meier curves. 
Adjusted HRs were stratified for potential effect modifiers 
including age, gender, duration of treated diabetes at 
CED, year of CED, use of thiazolidinediones (other than 
pioglitazone) prior to CED and history of renal compli-
cations and congestive heart failure (CHF) at CED. 
Primary analyses for each of the two mortality endpoints 
included all datasets in which the endpoint was recorded. 
A number of preplanned sensitivity analyses assessed 
the robustness of the results with respect to outcome, 
exposure and follow-up definitions and the inclusion 
of baseline smoking, baseline body mass index and TV 
HbA1c as covariates. These covariates were not available 
for the FIN and NL-HOSP populations and missing vari-
ables were treated as a separate category.
Further information
Further details about the study methodology are 
published in the BMJ20 and in the European Network 
of Centres for Pharmacoepidemiology and Pharma-
covigilance (ENCePP) E-register of studies (study title 
‘Pan-European Multi-Database Bladder Cancer Risk 
Characterisation Study’).
RESULTS
The complete 1:1 matched cohort included 56 337 
patients in both the pioglitazone-exposed and the non-ex-
posed groups. Descriptive statistics reported previously 
for the primary bladder cancer analyses20 demonstrated 
good covariate balance within the variables used in 
the matching process. The standardized differences 
for the proportion of patients with CHF, early cohort 
entry (2000–2003), and higher duration of medication 
database membership before CED (5–6 and 7+ years) 
marginally exceeded 10, the lower threshold that we set 
for good balance. Descriptive statistics for a selection of 
covariates are provided in table 1. The number of antidi-
abetic treatments prescribed at CED was similar in both 
cohorts. The most commonly prescribed treatment regi-
mens in the never exposed to pioglitazone group were 
insulin alone or in combination (36.99%), metformin or 
SU in combination (21.41%), or combinations of other 
antidiabetic drugs (31.10%). Pioglitazone was prescribed 
in a variety of treatment regimens: most commonly in 
combination with metformin (34.83%) or metformin 
and SU (24.25%).
A total of 10 513 deaths occurred during follow-up 
in the 1:1 matched cohort. There were 3370 deaths in 
the ever exposed to pioglitazone group during a mean 
follow-up time of 2.9 years, and 7143 deaths in the non-pi-
oglitazone-exposed group during a mean follow-up time 
of 2.8 years. The crude all-cause mortality rate per 10 000 
person-years was 206 (95% CI 199 to 213) for patients 
ever exposed to pioglitazone and 448 (95% CI 438 to 
458) for patients never exposed to pioglitazone. The 
Kaplan-Meier curve is consistent with the PH assumption 
(figure 1).
A statistically significant 33% reduction in all-cause 
mortality was observed for ever exposed to pioglitazone 
compared with never exposure to pioglitazone (adjusted 
HR 0.67, 95% CI 0.64 to 0.70). Observed reductions were 
statistically significant in five of the six datasets. Relative 
risk reduction ranged from 11% in the NL GP to 46% in 
Finland. In the 56 337 patients in the pioglitazone cohort, 
23 123 and 6462 patients received pioglitazone for at 
least 18 and 48 months, respectively. Total cumulative 
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Table 1 Distribution of a selection of matching and non-matching covariates at cohort entry
PIO exposed
n=56 337 n (%)
Non-PIO exposed
n=56 337 n (%)
Age at CED (years)
  40–49 6728 (11.94) 5608 (9.95)
  50–59 14 881 (26.41) 12 618 (22.40)
  60–69 18 366 (32.60) 17 262 (30.64)
  ≥70 16 362 (29.04) 20 849 (37.01)
  Range (min, max) (40, 102) (40, 106)
  Mean (±SD) 63.24 (10.86) 65.38 (11.56)
  Median (Q1, Q3) 63.00 (55.03, 71.00) 65.00 (57.00, 74.00)
Gender
  Male 31 732 (56.33) 30 561 (54.25)
  Female 24 605 (43.67) 25 776 (45.75)
Duration of treated diabetes at CED (years)
  <1 7805 (13.85) 7883 (13.99)
  1–<2 6943 (12.32) 6679 (11.86)
  2–<4 11 865 (21.06) 11 578 (20.55)
  4–<6 10 936 (19.41) 11 411 (20.25)
  ≥6 18 788 (33.35) 18 786 (33.35)
  Range (min, max) (0.00, 34.18) (0.00, 24.79)
  Mean (±SD) 4.72 (3.65) 4.78 (3.70)
  Median (Q1, Q3) 4.12 (1.76, 6.97) 4.19 (1.82, 6.97)
Use of other TZD medications prior to CED
  Never 41 847 (74.28) 41 847 (74.28)
  Ever 14 490 (25.72) 14 490 (25.72)
Antidiabetic treatment immediately prior to CED*
  Metformin only 16 526 (29.33) 16 526 (29.33)
  Sulphonylureas (SU) only 6110 (10.85) 6110 (10.85)
  Metformin and SU 14 277 (25.34) 14 277 (25.34)
  Insulin (only or in combination) 2705 (4.80) 2705 (4.80)
  Other drugs or combinations 10 062 (17.86) 10 062 (17.86)
  No treatment 6657 (11.82) 6657 (11.82)
Number of different antidiabetic drug classes being used at CED†
  1 6905 (12.26) 9961 (17.68)
  2 29 216 (51.86) 29 767 (52.84)
  3 18 446 (32.74) 15 917 (28.25)
  >3 1770 (3.14) 692 (1.23)
Antidiabetic treatment at CED†
  Metformin only 19 622 (34.83) 3496 (6.21)
  SU only 7442 (13.21) 2418 (4.29)
  Metformin and SU 13 659 (24.25) 12 062 (21.41)
  Insulin (only or in comb.) 2595 (4.61) 20 840 (36.99)
  Other drugs or comb. 6114 (10.85) 17 521 (31.10)
  No treatment 6905 (12.26) 0 (0.00)
Diabetic complications at CED
  Diabetic retinopathy or maculopathy 5747 (10.20) 5953 (10.57)
Continued
group.bmj.com on January 26, 2018 - Published by http://drc.bmj.com/Downloaded from 
5BMJ Open Diab Res Care 2017;5:e000364. doi:10.1136/bmjdrc-2016-000364
Epidemiology/Health Services Research
pioglitazone dose exceeded 14 000 mg for 22 550 patients 
and 40 000 mg for 7226 patients. Observed reductions 
were statistically significant for all doses and durations 
of exposure. The HR estimates for all-cause mortality 
are presented in figures 2 and 3. No additional variables 
met the inclusion criteria for confounders. The adjusted 
model therefore included age, gender, antidiabetic medi-
cations, PS quintiles, and all variables that were included 
in the PS model. Full model results are presented in the 
supplementary appendix.
For patients with current pioglitazone exposure, there 
was a significant 60% reduction in all-cause mortality 
compared with never exposure (HR 0.40, 95% CI 0.37 
to 0.43). With regard to cumulative dose and duration 
of pioglitazone use, a similar significant reduction in 
mortality risk was observed for all exposure strata.
A statistically significant reduction in mortality risk 
was observed in all stratified and sensitivity analyses. The 
adjusted HR for patients prescribed and not prescribed 
thiazolidinedione prior to cohort entry was 0.85 (95% CI 
0.74 to 0.97) and 0.64 (95% CI 0.61 to 0.68), respectively. 
This was the only stratified analysis in which the confi-
dence intervals did not overlap (figure 4).
The pooled dataset for the bladder cancer mortality 
analysis included 34 615 patients in the 1:1 matched 
pioglitazone and non-pioglitazone exposed groups. 
A total of 21 deaths due to bladder cancer occurred 
during follow-up including seven deaths in the 
pioglitazone-exposed group and 14 deaths in the non-pi-
oglitazone-exposed group during a mean follow-up 
time of 2.7 years in both groups. The crude bladder 
cancer-specific mortality rate per 10 000 person-years was 
0.75 (95% CI 0.36 to 1.57) for patients ever exposed to 
pioglitazone and 1.50 (95% CI 0.89 to 2.54) for patients 
never exposed to pioglitazone. A statistically non-sig-
nificant 39% reduction was observed in bladder cancer 
cause-specific mortality for ever exposed to pioglitazone 
compared with never exposed to pioglitazone (adjusted 
HR 0.61, 95% CI 0.23 to 1.67). The adjusted model only 
included all the predefined covariates. Due to the small 
number of events, additional covariates or other expo-
sure definitions were not considered.
DISCUSSION
Our analysis of this large pan-European retrospective 
cohort study found a statistically significant 33% reduc-
tion in risk of all-cause mortality in patients with T2DM 
whose antidiabetic therapy was modified to include 
pioglitazone compared with an alternative antidiabetic 
medication at the same stage of disease progression. 
PIO exposed
n=56 337 n (%)
Non-PIO exposed
n=56 337 n (%)
  Lower limb severe complications 1308 (2.32) 1530 (2.72)
  Diabetic renal complications 4771 (8.47) 4870 (8.64)
  Ketoacidosis 112 (0.20) 145 (0.26)
  Hyperosmolar/
  ketoacidotic coma
822 (1.46) 1280 (2.27)
Other comorbidities at CED
  Myocardial infarction or stroke 4676 (8.30) 6112 (10.85)
  Congestive heart failure 1674 (2.97) 3077 (5.46)
Year at CED
  2000–2003 3960 (7.03) 6485 (11.51)
  2004–2007 21 151 (37.54) 20 513 (36.41)
  2008–2011 31 226 (55.43) 29 339 (52.08)
*Treatments initiated at CED are not included.
†Treatments initiated at CED are included. For the pioglitazone-exposed group, the listed treatments are in addition to pioglitazone.
CED, cohort entry date; PIO, pioglitazone; TZD, thiazolidinedione.
Table 1 Continued 
Figure 1 Kaplan-Meier plot of association of exposure to 
pioglitazone with all-cause mortality in patients with type 
2 diabetes. Never: never exposed to pioglitazone. Ever: 
exposed to pioglitazone.
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Figure 2 Number of events, the crude incidence rate, and the crude and adjusted HR with 95% CI for the association 
between pioglitazone use and all-cause mortality. Crude model: pioglitazone exposure variable and a dataset identifier. 
Adjusted model: Crude model plus, age, gender, use of metformin, use of sulphonylureas, use of insulin, and use of other 
antidiabetic drugs, all exact matching variables, propensity scores as quintiles, all propensity score variables evaluated at 
cohort entry date.
Figure 3 Adjusted HRs with 95% CI for the association between pioglitazone use and all-cause mortality for each dataset. 
The HRs and 95% CIs are presented in the original scale and the figure is plotted in the log scale. FIN, Finland; SWE, 
Sweden; United Kingdom GP, UK general practitioner; UK GP-HOSP, UK linked dataset; NL HOSP, Netherlands hospital data; 
NL GP, NL general practitioner.
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Comparators included a full range of antidiabetic treat-
ment regimens from metformin alone (11%) to insulin 
used alone or in combination (36%). Findings for 
bladder cancer-specific mortality estimated a similar 36% 
decrease with broad CIs consistent with a 77% decrease 
or a 67% increase, reflecting the small number of cases.
General strengths and weaknesses of the study have 
been reported previously.20 The cohort matching and 
regression modeling processes were designed for the 
primary outcome of incident bladder cancer. There is 
therefore a risk that important covariates influencing the 
association between pioglitazone exposure and all-cause 
mortality were not included. The most common cause 
of death in patients with T2DM is cardiovascular compli-
cations.22 Cardiovascular comorbidities were included 
in the PS, although good balance was not achieved for 
CHF, 2.97% and 5.46% in the pioglitazone exposed and 
unexposed cohorts, respectively. Stratifying the analysis 
by presence and absence of CHF at CED demonstrated 
similar reductions of all-cause mortality for the pioglita-
zone-exposed and non-pioglitazone-exposed groups. The 
imbalance is therefore unlikely to have biased the find-
ings. Also, TV variables for cardiovascular comorbidities 
were included in the adjusted regression model. Variables 
such as socioeconomic status and general health may 
affect both choice of diabetic treatment and mortality 
risk.23 These were not included in the study protocol and 
would be difficult to measure consistently across datasets. 
They may therefore be residual confounders.
Observed risk reductions were statistically significant 
in five of the six datasets which supports the generaliz-
ability of our findings. The largest relative risk reduction 
was observed in Finland (HR 0.54, 95% CI 0.50 to 0.58) 
and the smallest in the NL GP dataset (HR 0.89, 95% CI 
0.71 to 1.11). This may reflect differences in available 
data or in the care pathway for diabetes in these coun-
tries. All of the countries in this study have a publically 
funded national health service with limited co-pay for 
Figure 4 Adjusted HRs with 95% CI for the association between pioglitazone use and all-cause mortality stratified by key 
variables. CED, cohort entry date; CHF, congestive heart failure; TZD, thiazolidinedione.
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antidiabetic drugs during the study period. Nevertheless, 
the observed reduction in mortality risk may be due to 
inadequate or inappropriate prescribing in the compar-
ator arm.
In agreement with our study, Mannucci’s meta-anal-
ysis demonstrated a statistically significant association of 
pioglitazone use with reduced all-cause mortality (OR 
0.30, 95% CI 0.14 to 0.63) in patients at relatively low 
risk of cardiovascular events and death.15 The primary 
endpoint for the majority of RCTs was HbA1c. Patients 
included in the meta-analysis had a mean diabetes dura-
tion of 6.6 years and mean HbA1c of 8.1%. This is similar 
to the mean 4.7 year duration of treated diabetes and 
mean HbA1c (where available) of 8.5% and 8.8% in 
the exposed and control arms, respectively, of our study. 
The major advantage of clinical trials compared with 
our study is that patients are randomized to treatment. 
This greatly reduces the risk of residual confounding 
compared with our observational study methodologies. 
However, trials included in the meta-analysis were gener-
ally of short duration (8–156 weeks) and counted zero 
or few mortality events (total 56). Our study had a mean 
follow-up of 2.9 years and counted a total of 10 513 deaths. 
The results of our study are consistent with an observa-
tional cohort study that demonstrated a 23% reduction 
in all-cause mortality with use compared with non-use of 
glitazones (primarily pioglitazone) in the UK.18 There 
were 597 deaths in the study cohort over an average 4.5 
years of follow-up time. Yang et al’s observational study17 
comparing first time users of insulin or pioglitazone in 
a US claims database also found a statistically significant 
decrease in risk of all-cause mortality in the pioglitazone 
cohort compared with the insulin cohort.
In contrast, the large PROactive trial found no statis-
tically significant reduction in all-cause mortality with 
pioglitazone use compared with placebo in either the 
3-year trial (HR 0.96, 95% CI 0.78 to 1.18) or the 10-year 
observational follow-up period (HR 0.93, 95% CI 0.84 
to 1.04).16 24 This study was designed to study the effects 
of pioglitazone on cardiovascular disease in high-risk 
patients with pre-existing macrovascular disease and 
T2DM. Similar results were found in the Insulin Resistance 
Intervention after Stroke (IRIS) trial, which measured 
the effects of pioglitazone on cardiovascular disease and 
all-cause mortality in prediabetic patients with a recent 
history of ischemic stroke or transient ischemic attack. By 
4.8 years, there was no statistically significant difference 
in all-cause mortality in the pioglitazone group compared 
with the placebo group (HR 0.93, 95% CI 0.73 to 1.17).
Pioglitazone is an agonist of peroxisome prolifera-
tor-activated receptor γ (PPAR-γ) indicated for treatment 
of T2DM. Data show that pioglitazone causes partial 
activation of PPAR-α. These actions modulate the 
transcription of genes with favorable effects on fat distri-
bution, lipid and protein metabolism, insulin sensitivity, 
plasma glucose, inflammation, and vascular endothe-
lial function.25 There are several potential mechanisms 
that could underlie the association of pioglitazone and 
reduced mortality. The overall changes induced by piogl-
itazone suggest a general improvement in various risk 
factors that might reduce cardiovascular morbidity and 
mortality.16 Evidence also indicates that pioglitazone 
reduces the levels of various cardiovascular risk param-
eters/inflammatory markers, such as highly sensitive 
C-reactive protein and carotid intima-media thickness, 
independently of its effect on glycemic control.26 These 
mechanisms could be the link between treatment and 
reduced risk of macrovascular disease in patients with 
diabetes ,16 but more research is needed to confirm this 
view.
Evidence indicates that patients with T2DM have 
reduced life expectancy compared with the general 
population.1 2 RCTs provide limited and inconclu-
sive evidence concerning the effect of pioglitazone on 
all-cause mortality.
CONCLUSIONS
This large, observational multidatabase European cohort 
study found that prescribing pioglitazone compared 
with an alternative treatment decision at the same stage 
of disease progression was associated with a reduction 
in all-cause mortality rate. Further observational and 
prospective studies that are specifically designed to test 
the association between pioglitazone use and all-cause 
mortality objective are required.
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